Catalyst Biosciences (NASDAQ:CBIO) Rating Maintained
New York: In a research report issued to investors and clients on Friday, 9 February, Chardan Capital kept their Buy rating on shares of Catalyst Biosciences (NASDAQ:CBIO). They currently have a $75.0 target price per share on the firm. Chardan Capital’s target gives a potential upside of 1,421.30 % from the company’s current stock price.
NASDAQ:CBIO is at the moment trading -4.64% lower at $4.73 as of 2:06 PM New York time. Catalyst Biosciences’s stock is 0% over the last 200 days. It has underperformed the S&P 500 Index, which has increased 6.00% over the same time period.
Catalyst Biosciences (NASDAQ:CBIO) Profile
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Catalyst Biosciences (NASDAQ:CBIO) traded down -4.64% on 9 February, hitting $4.73. A total of 169,181 shares of the company’s stock traded hands. This is down from average of 510,758 shares. Catalyst Biosciences has a 52 week low of $3.11 and a 52 week high of $21.3. The company has a market cap of $20.39 million and a P/E ratio of 0.
Get the latest Catalyst Biosciences (NASDAQ:CBIO) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Analysts at Chardan Capital Maintained their Buy rating for Catalyst Biosciences (NASDAQ:CBIO) with $75.0 TP appeared first on Octafinance.